Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma operating margin
Operating margin is operating income as a percentage of revenue.
Sutro Biopharma's operating margin for the twelve months ending Jun 30, 2026 was -319.6%. For fiscal 2025 it was -154.5%, against -384.3% the year before. The highest annual figure on record is 2.3% in fiscal 2016.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -154.5% | +229.8 |
| FY2024 | Dec 31, 2024 | -384.3% | −326.3 |
| FY2023 | Dec 31, 2023 | -58.1% | +132.2 |
| FY2022 | Dec 31, 2022 | -190.3% | −31.0 |
| FY2021 | Dec 31, 2021 | -159.2% | +7.1 |
| FY2020 | Dec 31, 2020 | -166.3% | −36.5 |
| FY2019 | Dec 31, 2019 | -129.8% | −32.9 |
| FY2018 | Dec 31, 2018 | -96.9% | −59.6 |
| FY2017 | Dec 31, 2017 | -37.2% | −39.5 |
| FY2016 | Dec 31, 2016 | 2.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -303.8% | −298.5 |
| Q1 FY2026 | Mar 31, 2026 | -204.2% | +189.6 |
| Q4 FY2025 | Dec 31, 2025 | -326.7% | +114.0 |
| Q3 FY2025 | Sep 30, 2025 | -499.9% | +297.2 |
| Q2 FY2025 | Jun 30, 2025 | -5.2% | +184.1 |
| Q1 FY2025 | Mar 31, 2025 | -393.8% | +41.3 |
| Q4 FY2024 | Dec 31, 2024 | -440.7% | −478.6 |
| Q3 FY2024 | Sep 30, 2024 | -797.2% | −537.1 |
| Q2 FY2024 | Jun 30, 2024 | -189.4% | +254.1 |
| Q1 FY2024 | Mar 31, 2024 | -435.0% | −101.8 |
| Q4 FY2023 | Dec 31, 2023 | 37.9% | +608.2 |
| Q3 FY2023 | Sep 30, 2023 | -260.1% | −175.7 |
| Q2 FY2023 | Jun 30, 2023 | -443.5% | −374.5 |
| Q1 FY2023 | Mar 31, 2023 | -333.3% | +330.3 |
| Q4 FY2022 | Dec 31, 2022 | -570.2% | −241.4 |
| Q3 FY2022 | Sep 30, 2022 | -84.3% | +322.8 |
| Q2 FY2022 | Jun 30, 2022 | -69.0% | −34.0 |
| Q1 FY2022 | Mar 31, 2022 | -663.6% | −533.9 |
| Q4 FY2021 | Dec 31, 2021 | -328.9% | −28.7 |
| Q3 FY2021 | Sep 30, 2021 | -407.1% | −347.5 |
| Q2 FY2021 | Jun 30, 2021 | -35.0% | +138.4 |
| Q1 FY2021 | Mar 31, 2021 | -129.7% | +138.5 |
| Q4 FY2020 | Dec 31, 2020 | -300.1% | −169.4 |
| Q3 FY2020 | Sep 30, 2020 | -59.6% | +44.2 |
| Q2 FY2020 | Jun 30, 2020 | -173.4% | −43.4 |
| Q1 FY2020 | Mar 31, 2020 | -268.2% | −102.9 |
| Q4 FY2019 | Dec 31, 2019 | -130.8% | −113.6 |
| Q3 FY2019 | Sep 30, 2019 | -103.7% | +25.9 |
| Q2 FY2019 | Jun 30, 2019 | -130.0% | +81.9 |
| Q1 FY2019 | Mar 31, 2019 | -165.3% | +36.7 |
| Q4 FY2018 | Dec 31, 2018 | -17.2% | +358.3 |
| Q3 FY2018 | Sep 30, 2018 | -129.6% | −123.5 |
| Q2 FY2018 | Jun 30, 2018 | -211.9% | – |
| Q1 FY2018 | Mar 31, 2018 | -202.0% | – |
| Q4 FY2017 | Dec 31, 2017 | -375.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -6.1% | – |
See a number that looks wrong?